Risk Stratification and Pharmacological Management in Patients with Idiopathic Ventricular Fibrillation
スポンサーリンク
概要
- 論文の詳細を見る
Little information is available regarding risk stratification and pharmacological management in patients with idiopathic ventricular fibrillation (IVF). Our group has reported that J-wave variation is risk-stratifying factor in IVF patients. In this session, we will introduce useful noninvasive techniques and pharmacological strategies in managing IVF patients. Part 1: We enrolled 22 IVF patients and investigated the pathophysiology of J waves by assessing risk markers that reflect electrophysiological abnormalities such as late potentials (LP) using a newly developed signal-averaging system, frequency-domain heart rate variability (FD-HRV), T-wave alternans, and so on. IVF patients with J waves had a high incidence of LP associating high frequency components (vagal tone index) on FD-HRV analysis, with night ascendancy. J waves may be more closely associated with depolarization abnormality and autonomic modulation than repolarization abnormality. Part 2: We enrolled 8 young IVF patients who had real life-threatening events. In two patients with J-wave variation, pharmacological therapy including class III antiarrhythmic drugs and β-blockers are ineffective. However, β-blockers were effective in two of three patients without J waves and in two of three patients without J-wave variation on 12-lead and Holter ECGs. Any pharmacological therapy is ineffective when J-wave variation was observed, but β-blockers are occasionally effective when such a phenomenon was not seen in young IVF patients.
著者
-
Ikeda Takanori
Department Of Cardiovascular Medicine Graduate School Of Medicine Kyoto University
-
Miwa Yosuke
Second Department Of Internal Medicine Kyorin University School Of Medicine
-
Abe Atsuko
Second Department Of Internal Medicine Kyorin University School Of Medicine
-
Ikeda Takanori
Department of Cardiovascular Medicine, Toho University Medical Center Tokyo
関連論文
- Effects of Intravenous Nifekalant as a Lifesaving Drug for Severe Ventricular Tachyarrhythmias Complicating Acute Coronary Syndrome
- PJ-577 The Antiplatelet Effect of Aspirin does not Change after 2-year Interval(PJ097,Cardiovascular Pharmacology (Clinical) (H),Poster Session (Japanese),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)
- 1 Three-Year Outcome of the PRospective Evaluation of VENtricular Tachyarrhythmic Events and Sudden Cardiac Death in Patients with Left Ventricular Dysfunction (PREVENT-SCD) Study(Late Breaking Clinical Trials I,The 73rd Annual Scientific Meeting of The J
- Clopidogrel Resistance in Japanese Patients Scheduled for Percutaneous Coronary Intervention(Ischemic Heart Disease)
- Evaluation of the Antiplatelet Effects of Cilostazol, a Phosphodiesterase 3 Inhibitor, by VASP Phosphorylation and Platelet Aggregation
- PJ-422 Platelet Aggregability under Aspirin Therapy in Smoker is Higher than That in Non-smoker(Cardiovascular pharmacology, basic/clinical(05)(H),Poster Session(Japanese),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)
- PJ-421 Anti-platelet Effects of Statins in Patients under Aspirin Therapies(Cardiovascular pharmacology, basic/clinical(05)(H),Poster Session(Japanese),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)
- 5 Interim analyses of PRospective Evaluation of VENtricular Tachyarrhythmic events and Sudden Cardiac Death in patients with left ventricular dysfunction (PREVENT-SCD) study(Late Breaking Clinical Trials II,Special Program,The 72nd Annual Scientific Meeti
- Differences in Vagal and Sympathetic Effects on Excitation Wave Dynamics of Paroxysmal Atrial Fibrillation : A Simulation Study
- Importance of Wavefront Organization and Widened Excitable Gap in Terminating Atrial Fibrillation by Pilsicainide